Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome

被引:40
作者
Evans, Sydney M.
Du, Kevin L.
Chalian, Ara A.
Mick, Rosemarie
Zhang, Paul J.
Hahn, Stephen M.
Quon, Harry
Lustig, Robert
Weinstein, Gregory S.
Koch, Cameron J.
机构
[1] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 04期
关键词
hypoxia; EF5; nitroimidazole; head and neck cancer; squamous cell carcinoma;
D O I
10.1016/j.ijrobp.2007.04.067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: EF5, a 2-nitroimidazole hypoxia marker, was used to study the presence, levels, and prognostic significance of hypoxia in primary head and neck squamous cell tumors. Methods and Materials: Twenty-two patients with newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, or larynx with at least 2 years of clinical follow-up were included in this study. Quantitative analyses of EF5 immunofluorescence was carried out, and these data were compared with patient outcome. Results: EF5 immunostaining showed substantial intra- and intertumoral hypoxic heterogeneity. The majority of cells in all tumors were well oxygenated. Three patterns of EF5 binding in cells were identified using criteria based on the cellular region that was stained (peripheral or central) and the relationship of binding to necrosis. We tested the association between EF5-binding levels with event-free and overall survival irrespective of the pattern of cellular binding or treatment regimen. Patients with tumors containing EF5-binding regions corresponding to severe hypoxia (<= 0.1% oxygen) had a shorter event-free survival time than patients with pO(2) values greater than 0.1% (p = 0.032). Nodal status was also predictive for outcome. Conclusions: These data illustrate the potential utility of EF5 binding based on quantitative immunohistochemistry of tissue pO(2) and provide support for the development of noninvasive hypoxia positron emission tomographic studies with fluorine 18-labeled EF5. (c) 2007 Elsevier Inc.
引用
收藏
页码:1024 / 1031
页数:8
相关论文
共 51 条
[1]   Functional significance of erythropoietin receptor expression in breast cancer [J].
Arcasoy, MO ;
Amin, K ;
Karayal, AF ;
Chou, SC ;
Raleigh, JA ;
Varia, MA ;
Haroon, ZA .
LABORATORY INVESTIGATION, 2002, 82 (07) :911-918
[2]  
Azuma Y, 2003, CLIN CANCER RES, V9, P4944
[3]   Oxygenation of squamous cell carcinoma of the head and neck:: Comparison of primary tumors, neck node metastases, and normal tissue [J].
Becker, A ;
Hänsgen, G ;
Bloching, M ;
Weigel, C ;
Lautenschläger, C ;
Dunst, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01) :35-41
[4]  
Brizel DM, 1996, CANCER RES, V56, P941
[5]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[6]   Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck [J].
Brizel, DM ;
Sibley, GS ;
Prosnitz, LR ;
Scher, RL ;
Dewhirst, MW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (02) :285-289
[7]   Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447
[8]  
Busch TM, 2003, ADV EXP MED BIOL, V510, P37
[9]   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J].
Calais, G ;
Alfonsi, M ;
Bardet, E ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Oudinot, P ;
Bertrand, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) :2081-2086
[10]   FINAL REPORT OF THE PHASE-I TRIAL OF THE HYPOXIC CELL RADIOSENSITIZER SR-2508 (ETANIDAZOLE) RADIATION-THERAPY ONCOLOGY GROUP-83-03 [J].
COLEMAN, CN ;
WASSERMAN, TH ;
URTASUN, RC ;
HALSEY, J ;
NOLL, L ;
HANCOCK, S ;
PHILLIPS, TL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (02) :389-393